Ryo Kawakami

This study shows BCKDK inhibitors cause vasodilation by directly blocking the AT1R, independent of BCAA catabolism or BCKDK.

This study identifies that SGLT2 inhibitors activate pantothenate kinase 1 (PANK1) in the human heart, enhancing coenzyme-A synthesis and fuel use, which may explain their clinical benefits in heart failure.

This study shows that pancreas-specific BCKDK inhibition accelerates pancreatic cancer while systemic BCKDK inhibition reduces tumor formation.

This study shows that BT2, an inhibitor of BCKDK, reduces plasma tryptophan by displacing it from albumin, revealing an off-target effect on tryptophan metabolism.